Healthcare Industry News: Elekta
News Release - April 2, 2012
Elekta's New Agility MLC Solution Poised to Revolutionize Beam Shaping of Radiation Therapy Cancer TreatmentsElekta has received clearance to CE mark its new multileaf collimator (MLC)
CRAWLEY, England, April 2, 2012 -- (Healthcare Sales & Marketing Network) -- Elekta announced today it has received clearance to CE mark Agility™*, a revolutionary beam-shaping device integrated into the head of a linear accelerator (linac). Patients and clinics will benefit from the speed and reliability of this new MLC design.
"According to WHO, cancer is a leading cause of death worldwide, and the incidence is expected to continue rising significantly," says Tomas Puusepp, President and CEO of Elekta. "To meet this increasing need, we have collaborated closely with leading hospitals and research institutions to develop a solution that can increase the throughput of patients while delivering outstanding precision. I'm proud to see that one of our largest projects ever is now ready to contribute to improving cancer care treatment."
He adds: "Modern cancer treatment is very complex and continues to be even more so. And it's vital to be able to shape a radiation beam with high precision to avoid harming surrounding tissue, while maintaining time efficiency. Agility is designed to meet these demands. When it reaches the market, hundreds of thousands of patients will benefit from this unique device every year."
Agility's leaf speeds are twice as fast as other MLCs commonly used within the industry. This means shorter treatment times for patients, while hospitals or clinics are able to treat patients more efficiently.
With twice as many leaves as a standard MLC, Agility will enable clinicians to sculpt delivered radiation doses to the unique contours of tumors with extreme precision. Clinicians can be confident that the leaves are producing the correct shape to deliver the prescribed treatment to the patient.
Reducing unwanted dose to healthy tissue or organs at risk is of primary importance. Consequently, Agility's leafbank is designed for extraordinarily low transmission.
"For our patients, the use of Agility with VMAT delivery will allow us to administer Stereotactic Body Radiation Therapy (SBRT) more quickly and efficiently than our current fixed-field approach," says Vivian Cosgrove, Ph.D., head of radiotherapy physics at St. James's University Hospital, Leeds, UK. "The speed of leaf movement possible with Agility will work in harmony with other technological developments – such as higher dose rate, Flattening Filter Free** (FFF) beams – so that further improvements can be made to SBRT deliveries."
Agility can be purchased as part of a new radiotherapy solution from Elekta, as well as an upgrade option to a large part of Elekta's installed base of linear accelerators. This enables clinics to maximize the potential of their existing equipment.
Agility features include:
160 tungsten leaves, only 5mm thin, with a leaf speed of up to 6.5cm per second.
High-performance reliability and precision using Elekta's novel Rubicon™ optical positioning system.
Dedicated Integrity™ R3.0 software, Elekta's seventh generation digital control system, to precisely coordinate leaf movements with variable dose delivery rates and other treatment parameters.
Integrated dynamic leaf guides streamline delivery and eliminate the need for "split fields" commonplace with other MLC systems.
Large-field MLC will enable clinicians to shape radiation across fields of up to 40 x 40cm, providing a highly versatile single solution for a broad spectrum of therapies.
Watch the Agility video (http://www.youtube.com/watch?v=p-IrnaPx6IA) and read more in the white paper: Agility, Intelligent design (http://www.Elekta.com/dms/Elekta/Elekta-assets/proof/Oncology/Physics/Other/WP-Agility---Intelligent-Design/WP%20Agility%20-%20Intelligent%20Design.pdf)
*Agility is not available for sale or distribution in all markets. Please contact the local Elekta representative for details.
** Flattening Filter Free is work in progress and not available for sale in all regions.
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 on April 2, 2012.
For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email: stina.thorman@Elekta.com
Time zone: CET: Central European Time
Michelle Lee Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@Elekta.com
Time zone: ET: Eastern Time
Johan Andersson Melbi, Investor Relations Manager, Elekta AB (publ)
Tel: +46 702 100 451, email: johan.anderssonmelbi@Elekta.com
Time zone: CET: Central European Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.